Mannkind Corp. (MNKD)
NASDAQ:MNKD
Want to see MNKD full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
>-0.01Last Year’s EPS
0Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted multiple near-term commercial and clinical catalysts, solid top-line growth (15% YoY) and strong operational wins (FURO6 prescriber growth, royalties up 9%, SC Pharma synergies exceeding $20M), alongside meaningful progress on pipeline programs (MNKD-201 Phase 1b and Phase 2 start) and an expanded collaboration with United Therapeutics (ralinepag DPI payment and milestone potential). Short-term challenges include seasonality, field reorganization and inventory transitions that pressured Q1 revenue and contributed to GAAP and non-GAAP losses, plus some formulation and development uncertainty for new DPI programs. Management reiterated full-year FURO6 guidance and expects acceleration in H2 tied to the ReadyFlow auto-injector and Afrezza pediatrics launch, indicating confidence that near-term investments will drive longer-term growth.Company Guidance
Quarterly Revenue Growth
Total Q1 2026 revenues of $90.0M, up 15% year-over-year, driven in part by the inclusion of FURO6 following the SC Pharma acquisition.
FURO6 Commercial Momentum
FURO6 net sales of $15.5M in Q1; record number of prescribers with 75% repeat writers; doses dispensed grew 64% year-over-year and doses dispensed were reported up nearly 60% through April versus the same period last year. Company reaffirmed full-year FURO6 revenue guidance of $110M–$120M.
Afrezza Performance and Pediatric Readiness
Afrezza global net sales of $15.3M, up 3% year-over-year. FDA updated Afrezza label to provide clear pediatric starting dose guidance; launch buildout for Afrezza Pediatrics completed ahead of the May 29 PDUFA date. Broad addressable opportunity noted (38M patients in current indications; ~360k ages 8–22 with type 1 diabetes in U.S.).
United Therapeutics Collaboration & Near-Term Milestones
Received $5.0M upfront payment for advancing ralinepag DPI; potential to receive up to $35M in development milestones plus a 10% royalty on net sales. Company expects approximately $15M of those milestones to be earned over the next 12 months.
Manufacturing Durability: Tyvaso DPI Supply Agreement
MannKind confirmed as sole manufacturer of Tyvaso DPI under a supply agreement that includes contractual minimums, providing a more predictable annual manufacturing revenue base.
Royalties and Cash Generation
Q1 royalties increased 9% year-over-year to $32.7M, supporting capital priorities including debt retirement and pipeline funding.
SC Pharma Integration and Synergies
Integration ~7 months post-close with integration largely complete for most functions; identified synergies exceeded the previously stated $20M annual target.
Pipeline Progress: MNKD-201 (nintedanib DPI)
Phase 1b Cohort 1 in IPF patients completed with no discontinuations due to cough or serious adverse events in first 12 patients; top-line Phase 1b data expected in Q3 2026. Global Phase 2 enrollment initiated this quarter to accelerate development.
MNKD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MNKD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $3.56 | ― | ― |
Feb 26, 2026 | $3.50 | $3.24 | -7.43% |
Nov 05, 2025 | $5.48 | $6.06 | +10.58% |
Aug 06, 2025 | $3.99 | $3.46 | -13.16% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Mannkind Corp. (MNKD) report earnings?
Mannkind Corp. (MNKD) is schdueled to report earning on Aug 12, 2026, TBA (Confirmed).
What is Mannkind Corp. (MNKD) earnings time?
Mannkind Corp. (MNKD) earnings time is at Aug 12, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MNKD EPS forecast?
MNKD EPS forecast for the fiscal quarter 2026 (Q2) is >-0.01.